Selected data models

You must log in to select data models for download or further analysis.

21 Search results.
Relevance Rating New first Old first

Eligibility NCT00321464 Bone Metastases in Subjects With Advanced Breast Cancer - Eligibility

- 4/14/14 - 1 form, 2 itemgroups, 8 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00321464

Prostate Cancer NCT00079001 On-Study - CALGB 90202: Skeletal Survey Form - 2083769v3.0 - CALGB 90202: Skeletal Survey Form

- 1/9/15 - 1 form, 1 itemgroup, 22 items, 1 language
Itemgroup: CCRR MODULE
CALGB 90202: Skeletal Survey Form Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B7BE7E12-C8DF-7003-E034-0003BA12F5E7

Metastatic Cancer NCT00134056 Response - Southwest Oncology Group - Bisphosphonate Usage Form - 2759910v1.0 - Southwest Oncology Group - Bisphosphonate Usage Form

- 1/9/15 - 1 form, 3 itemgroups, 19 items, 1 language
Itemgroups: Header, Header, Comments
Southwest Oncology Group - Bisphosphonate Usage Form Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4FD609AB-09CA-1C94-E044-0003BA3F9857

Metastatic Cancer NCT00134056 Pre-Study - SOUTHWEST ONCOLOGY GROUP Prestudy Form (S0421) - 2306139v3.0 - SOUTHWEST ONCOLOGY GROUP Prestudy Form (S0421)

- 1/9/15 - 1 form, 8 itemgroups, 79 items, 1 language
Itemgroups: Header, PATIENT AND DISEASE DESCRIPTION, Laboratory Values, Associated Correlative Science Consent, Additional Prestudy Data, DISTANT METASTATIC DISEASE, Prior Treatment Related To This Cancer, Comments
SOUTHWEST ONCOLOGY GROUP Prestudy Form (S0421) Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F1F9786C-0716-36C3-E034-0003BA3F9857

Metastatic Cancer NCT00134056 Follow-Up - SOUTHWEST ONCOLOGY GROUP FOLLOW UP FORM - 2305135v3.0 - SOUTHWEST ONCOLOGY GROUP FOLLOW UP FORM

- 1/9/15 - 1 form, 3 itemgroups, 27 items, 1 language
Itemgroups: Header, VITAL STATUS, Comments
SOUTHWEST ONCOLOGY GROUP FOLLOW UP FORM Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F159EF7E-D486-319F-E034-0003BA3F9857

Metastatic Cancer NCT00134056 Response - SOUTHWEST ONCOLOGY GROUP PROSTATIC SPECIFIC ANTIGEN REPORTING FORM - 2304629v3.0 - SOUTHWEST ONCOLOGY GROUP PROSTATIC SPECIFIC ANTIGEN REPORTING FORM

- 1/9/15 - 1 form, 3 itemgroups, 12 items, 1 language
Itemgroups: Header, PSA MEASUREMENTS, Comments
SOUTHWEST ONCOLOGY GROUP PROSTATIC SPECIFIC ANTIGEN REPORTING FORM Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F159832A-A1FF-27F6-E034-0003BA3F9857

Radium-223 Dichloride (Alpharadin) DRKS00006460 NCT01618370 in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases - Radium 223 Dichloride (Alpharadin) - Screening Visit

- 2/13/17 - 1 form, 9 itemgroups, 89 items, 1 language
Itemgroups: Demography, Vital Signs, Prostate Cancer Classification, BPI-SF, ECOG Performance Status, Prior radiotherapy, Prior diagnostic and therapeutic procedures for prostate cancer, Hematology (with DBC), General chemistry - Serum
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product. NCT01618370

Metastatic Cancer NCT00134056 Toxicity - SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE EVENT FORM: Step 1 Randomization - 2305232v3.0 - SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE EVENT FORM: Step 1 Randomization

- 1/9/15 - 1 form, 3 itemgroups, 20 items, 1 language
Itemgroups: Header, ADVERSE EVENTS, Comments
SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE EVENT FORM: Step 1 Randomization Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F15B0C64-8BEB-3314-E034-0003BA3F9857

Metastatic Cancer NCT00134056 Toxicity - SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE EVENT SUMMARY FORM: Step 2 Post-Chemo Form - 2464820v1.0 - SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE EVENT SUMMARY FORM: Step 2 Post-Chemo Form

- 1/9/15 - 1 form, 3 itemgroups, 20 items, 1 language
Itemgroups: Header, ADVERSE EVENTS, Comments
SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE EVENT SUMMARY FORM: Step 2 Post-Chemo Form Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0F9D4F4F-BA23-2F60-E044-0003BA3F9857

Southwest Oncology Group Registration Form (S0421) NCT00134056

- 9/20/21 - 1 form, 3 itemgroups, 40 items, 1 language
Itemgroups: Header, Patient demographics, Miscellaneous Patient Information
Southwest Oncology Group Registration Form (S0421) NCT00134056 Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F15A11DF-588A-2157-E034-0003BA3F9857

Southwest Oncology Group S0421 FACT-P Questionnaire: Step 1 Randomization Form NCT00134056

- 9/20/21 - 1 form, 3 itemgroups, 53 items, 1 language
Itemgroups: Header, Randomization questions, Patient status assessment
Southwest Oncology Group S0421 FACT-P Questionnaire: Step 1 Randomization Form NCT00134056 Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F159B9D6-FD84-2C7B-E034-0003BA3F9857

Eligibility Bone Metastases NCT02226276

- 9/20/21 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02226276

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial